Your browser doesn't support javascript.
loading
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Costa, Luciano J; Derman, Benjamin A; Bal, Susan; Sidana, Surbhi; Chhabra, Saurabh; Silbermann, Rebecca; Ye, Jing C; Cook, Gordon; Cornell, Robert F; Holstein, Sarah A; Shi, Qian; Omel, James; Callander, Natalie S; Chng, Wee Joo; Hungria, Vania; Maiolino, Angelo; Stadtmauer, Edward; Giralt, Sergio; Pasquini, Marcelo; Jakubowiak, Andrzej J; Morgan, Gareth J; Krishnan, Amrita; Jackson, Graham H; Mohty, Mohamad; Mateos, Maria Victoria; Dimopoulos, Meletious A; Facon, Thierry; Spencer, Andrew; Miguel, Jesus San; Hari, Parameswaran; Usmani, Saad Z; Manier, Salomon; McCarthy, Phillip; Kumar, Shaji; Gay, Francesca; Paiva, Bruno.
Afiliação
  • Costa LJ; Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu.
  • Derman BA; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
  • Bal S; Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Sidana S; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Chhabra S; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Silbermann R; Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
  • Ye JC; Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
  • Cook G; Haematology & Myeloma Studies, Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Cornell RF; Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Holstein SA; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
  • Shi Q; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Omel J; Independent Patient Advocate, Omaha, NE, USA.
  • Callander NS; Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.
  • Chng WJ; National University Health System, Singapore, Singapore.
  • Hungria V; Clinica São Germano, São Paulo, Brazil.
  • Maiolino A; Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Stadtmauer E; University of Pennsylvania, Philadelphia, PA, USA.
  • Giralt S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pasquini M; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Jakubowiak AJ; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
  • Morgan GJ; New York University Langone Health, New York, NY, USA.
  • Krishnan A; City of Hope, Duarte, CA, USA.
  • Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Mohty M; Hôpital Saint-Antoine, Paris, France.
  • Mateos MV; Department of Haematology, University Hospital of Salamanca, Salamanca, Spain.
  • Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Facon T; Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU) Lille, University of Lille, Lille, France.
  • Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VA, Australia.
  • Miguel JS; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.
  • Hari P; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Usmani SZ; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA.
  • Manier S; Department of Hematology, Université de Lille, CHU, Lille, France.
  • McCarthy P; Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Kumar S; Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
  • Gay F; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
  • Paiva B; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.
Leukemia ; 35(1): 18-30, 2021 01.
Article em En | MEDLINE | ID: mdl-32778736
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasia Residual / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Guideline / Screening_studies Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasia Residual / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Guideline / Screening_studies Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido